Cangrelor Neonatal PK/PD and Safety Study

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 3, 2017

Primary Completion Date

August 31, 2019

Study Completion Date

December 23, 2019

Conditions

Partial Obstruction of Systemic to Pulmonary Artery ShuntComplete Obstruction of Systemic to Pulmonary Artery Shunt

Interventions

DRUG

Cangrelor

Trial Locations (2)

Columbia University Medical Center, New York

UPMC Children's Hospital of Pittsburgh, Pittsburgh

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT02765633 - Cangrelor Neonatal PK/PD and Safety Study | Biotech Hunter | Biotech Hunter